Trial Profile
A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tideglusib (Primary)
- Indications Progressive supranuclear palsy
- Focus Therapeutic Use
- Acronyms TAUROS
- Sponsors Noscira
- 24 Apr 2017 Results of a post-hoc analysis from NCT01110720 and NCT01049399 studies, published in the Movement Disorders.
- 14 Feb 2014 Results published in the Movement Disorders.
- 31 Jan 2014 Results published in the Movement Disorders.